ARTICLE SUMMARY:
The demand for blood sampling is greater than ever before, driven by the increasing incidence of chronic disease and traumatic accidents and new applications for genomic testing. As healthcare institutions struggle with a dearth of staff that can perform blood draws on augmenting numbers of patients, the market demands solutions that can disrupt the bottleneck and provide swift care while freeing up doctors, nurses, and phlebotomists to use their time and skills more efficiently.
Drawing blood has always been an essential part of healthcare, often the first step in reaching a diagnosis and a reliable way to get a status update for an ongoing condition. Now, with COVID-19 rapidly elevating the importance of minimal-contact, remote, and automated medicine both to mitigate infection and to avoid diverting precious clinical resources, a major need for new, scalable blood collection technologies has been highlighted.
Because blood analysis occurs so frequently and has so many discrete applications, more than one approach is required to bring the greater industry into the contemporary era. Fortunately, innovative start-ups worldwide are answering the call, making the latest technologies accessible and consistent in a variety of settings. These companies aim to take their share of a global market for blood collection worth about $6.8 billion in 2022, according to a July 2022 report from Reportlinker.com.
